A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

BENGT SORBE1, MARIANNE GRAFLUND1, LISA NYGREN1 and GYÖRGY HORVÁTH2

1Department of Oncology, University Hospital, Örebro; 2Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden

Received July 22, 2012; Accepted December 28, 2012

DOI: 10.3892/ol.2013.1146

Abstract. The purpose of this study was to compare the toxicity profiles of docetaxel administered on a weekly schedule and the standard three-week schedule in the treatment of advanced primary ovarian carcinoma. Eligible patients were treated with intravenous docetaxel (30 mg/m²) on days 1, 8 and 15, and carboplatin (AUC 5) on day 1 or with docetaxel (75 mg/m²) and carboplatin (AUC 5) on day 1; Q21 days for 6 cycles. This study was a pooled study of two primary phase II studies. A total of 108 patients received the weekly schedule and 59 patients received the three-week schedule. All patients were evaluated for toxicity. The overall response rate was 79% and the biochemical response 93% for the weekly schedule. The median overall survival rate was 35.3 months. Neutropenia was significantly more common (ANOVA; p<0.0001) in the three-week group than in the weekly group during all six courses of chemotherapy. Fever and infections were also more common in this group. Thrombocytopenia and anemia were slightly more common in the weekly group. Fatigue, epiphora, nail changes and taste disturbances were specific side-effects following weekly docetaxel. Peripheral sensory neuropathy (grade 1-2) increased with every cycle of treatment, but in a similar manner in the two groups. Grade 3-4 neuropathy was not recorded. Oral mucositis and myalgia were two side-effects associated with the three-week schedule. Nausea and vomiting, diarrhea and dyspnea were a limited problem in both groups. Cardiac toxicity was rare and did not differ between the two docetaxel schedules. The weekly administration was favored due to the lower rates of neutropenia, fever, infections, oral mucositis and myalgia. However, epiphora and nail changes were specific side-effects of the weekly treatment. Both regimens appeared to be rather well tolerated with similar compliance (66 and 70%) with regard to completion of the planned six courses of chemotherapy.

Introduction

Cancer of the ovary is the seventh most common type of cancer in females, accounting for almost 225,000 new cases and 140,000 mortalities annually (1). Efficacy of first-line chemotherapy with paclitaxel and carboplatin is impressive; however, 70% of patients will eventually succumb to disease-related complications during long-term follow-up. New chemotherapy agents and alternative dosing schedules have been investigated to improve responses and survival rates and to increase tolerability (2-5). Standard 3-week dosing schedules have improved response rates and progression-free survival, but long-term overall survival rates are less impressive and relapses continue to exceed 70% (3).

Studies have analyzed the efficacy of primary therapy, but data have not shown the superiority of a specific standard triplet chemotherapy regimen for the treatment of ovarian carcinoma (3).

Weekly chemotherapy regimens have been evaluated with regard to improved prognosis and reduced or altered drug toxicity. Promising activity and a favorable toxicity profile have been reported (4,5). A higher total dose of paclitaxel (dose-dense) may be achieved with weekly regimens and may theoretically be superior to the standard 3-week schedule for first-line therapy (6).

Docetaxel is an alternative to paclitaxel in combination with a platinum agent in first-line chemotherapy, but also for the treatment of recurrent ovarian cancer (7,8). The standard three-week schedule appears to be of comparable efficacy with paclitaxel but with a different toxicity profile (9). More dose-dense weekly schedules have also been studied in small patient series of recurrent ovarian cancer (10-16). New data on up-front weekly docetaxel with regard to efficacy, toxicity and quality of life have recently been presented (17,18).

The purpose of the present study was to compare the toxicity profiles of weekly docetaxel administration and the standard three-week schedule for primary therapy of advanced ovarian carcinoma. In both schedules carboplatin was admin-
istered every three weeks. Efficacy and quality-of-life data have been presented previously and are not analyzed in this study (17,18).

Patients and methods

Eligibility. This was a retrospective comparative multicenter study, including patients with histologically confirmed epithelial ovarian carcinoma from the Gynecological Oncology departments at two university hospitals (Örebro and Gothenburg) in Sweden. All patients were in FIGO stage IIB-IV and underwent primary cytoreductive surgery. The period of recruitment was from May 2003 to December 2008. In all, 167 patients were included in the study and 108 patients received weekly docetaxel (Örebro) and 59 received docetaxel every three weeks (Gothenburg) together with carboplatin given every three weeks in both regimens. Of these patients, 147 (88%) completed 3 or more courses of chemotherapy. Clinical and biochemical response rates were based on patients with measurable disease and/or elevated CA-125 levels at the start of chemotherapy. The results from a phase II study of weekly treatment have been published previously (17). Toxicity, which is the main topic of this study, was recorded in all 167 patients (≥1 course of chemotherapy). Patient and tumor characteristics are shown in Table I.

A chemotherapy regimen of weekly docetaxel 30 mg/m² and carboplatin [area under the curve (AUC) 5] was given every 3 weeks to 108 patients (17). Six cycles were administered during 18 weeks. Of these patients, 71 (66%) completed 6 cycles of chemotherapy. The mean dose intensity of docetaxel was 29.8 mg/m²/week (95% CI, 29.6-29.9) and of carboplatin 105.7 mg/m²/week (95% CI, 102.0-109.5).

A chemotherapy regimen of docetaxel 75 mg/m² and carboplatin (AUC 5) was given every 3 weeks to 59 patients (9). Six cycles were administered during 18 weeks. Of these patients, 41 (70%) completed 6 cycles of chemotherapy. The mean dose intensity of docetaxel was 25.1 mg/m²/week (95% CI, 24.9-25.3) and of carboplatin 109.4 mg/m²/week (95% CI, 105.5-113.3).

Eligible patients had adequate bone marrow, renal and hepatic function, and an absolute neutrophil count (ANC) ≥1.5x10⁹/l, a platelet count ≥100x10⁹/l, serum-creatinine ≤1.25 times the normal level, serum ASAT/ALAT ≤1.5 times the normal level, no previous history of chemotherapy or radiotherapy, and an Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Exclusion criteria included severe infection, hypertension and myocardial infarction within the previous 6 months, congestive heart failure, prior serious allergic reactions and previous malignancy within 5 years. The study was approved by the Ethics Committees of the participating University Hospitals (Dnr 03-258). Informed consent was obtained from all patients.

Drug administration. Patients were treated with intravenous docetaxel (30 mg/m²) and carboplatin (AUC 5) on day 1. Docetaxel was repeated on days 8 and 15 and was administered via a ½-hour infusion. Carboplatin was administered in accordance with the Calvert formula (19) for 30 min on day 1. In the group with standard chemotherapy, intravenous docetaxel (75 mg/m²) and carboplatin (AUC 5) were both given on day 1. The second course started on day 22. Before docetaxel infusion, patients were premedicated with intravenous dexamethasone, diphenhydramine and a histamine H₁-receptor antagonist, such as cimetidine. The creatinine clearance was calculated by the method of Cockcroft and Gault (20).

Response evaluation. Clinical response was assessed at the completion of 6 chemotherapy cycles (or after at least 3 completed cycles) via clinical, radiographic and serologic means in accordance with the WHO response criteria (21) and the Rustin criteria (22). Patients with residual disease at the start of chemotherapy and who completed at least 3 cycles of chemotherapy (n=85) were evaluable for clinical response evaluation. Efficacy data of weekly therapy have been presented in an earlier report (17). In the present study efficacy data were not further analyzed.

Toxicity analysis. Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v3.0, 2003) (23). Patients were required to have an ANC ≥1.5x10⁹/l and a platelet count ≥100x10⁹/l on day 1 to receive chemotherapy. Complete blood cell values were obtained weekly until the conclusion of cycle 6 and then subsequently, every 3 weeks. Adequate renal function was defined as serum creatinine <1.25 times the upper normal limit, and liver function of bilirubin < upper normal limit, AST/ALT <1.5 times the

| Table I. Patient characteristics for the series of weekly vs. three-week docetaxel-carboplatin administrations (n=167). |
|------------------------------------------------------------------------------------------------------------------|
| **Characteristics** | **One-week group** | **Three-week group** |
| Mean age, years | 63.3 (range, 28-80) | 63.6 (range 47-79) |
| Body mass index (BMI) | 23.8 | 23.8 |
| Body surface area (BSA), m² | 1.69 | 1.67 |
| Histological type, n (%) | | |
| Papillary serous | 95 (88.0) | 45 (76.3) |
| Mucinous | 2 (1.9) | 0 (0.0) |
| Endometrioid | 4 (3.7) | 9 (15.3) |
| Clear cell | 7 (6.5) | 3 (5.1) |
| Anaplastic | 0 (0.0) | 2 (3.4) |
| FIGO stage, n (%) | | |
| IIB | 1 (0.9) | 1 (1.7) |
| IIC | 4 (3.7) | 4 (6.8) |
| IIIA | 3 (2.8) | 2 (3.4) |
| IIIB | 3 (2.8) | 8 (13.6) |
| IIIC | 63 (58.3) | 31 (52.5) |
| IV | 34 (31.5) | 13 (22.0) |
| Differentiation grade, n (%) | | |
| Poor | 67 (62.0) | 37 (62.7) |
| Moderate | 29 (26.9) | 16 (27.1) |
| Well | 5 (4.6) | 3 (5.1) |
| Not graded (clear cell) | 7 (6.5) | 3 (5.1) |
Fatigue was the most common symptom. 29 patients exhibited a partial response (34.1%), resulting in a total clinical response rate of 78.8% (95% CI, 70.1-87.5%). Data from the three-week schedule showed a clinical response rate of 88.7% (95% CI, 80.2-97.2%).

In the weekly schedule the median overall survival time was 35.3 months and the progression-free survival time was 12.0 months. The corresponding figures in the three-week schedule were 54.1 and 20.0 months, respectively.

Since this was not a randomized study, response and survival data could not be compared between the weekly and the three-week schedule due to differences in the study populations; this was not the purpose of the study.

### Toxicity

**Hematological toxicity.** Grade 3-4 neutropenia was recorded in 8 patients (11.3%) in the one-week group and in 32 patients (78.1%) in the three-week group after six completed courses of chemotherapy. This was a highly significant difference (Table II). Grade 1-2 neutropenia was recorded in 29 patients (40.9%) and 6 patients (14.6%) in the two groups, respectively.

During all six courses of chemotherapy the mean neutrophil count was significantly lower in the three-week group compared with the one-week group (ANOVA; p<0.0001). A time-dependent effect was also observed in the one-week group with successively decreasing mean values from cycle 1 to cycle 5. This time-dependent pattern was not observed in the three-week group, with low but stable mean values from cycles 1-6 (Fig. 1).

Febrile neutropenia and septicemia were also more frequent in the three-week group (Table III).

Grade 3-4 thrombocytopenia was recorded in one patient in the one-week group and in no patients in the three-week group. However, grade 1-2 thrombocytopenia was more frequent in the one-week group (50.7%) than in the three-week group (14.6%). The thrombocytic toxicity was more pronounced in the one-week-group and significantly increased with every chemotherapy cycle administered. In the three-week group this pattern was not observed.

None of the patients exhibited grade 3-4 anemia. Grade 1-2 anemia was more frequent in the one-week group (95.8%) than in the three-week group (73.2%). The degree of anemia increased with every successive course of chemotherapy and in a similar manner for both treatment groups. All of these differences were statistically significant (Table II). Despite the different pattern of hematological toxicity, the compliance rate with the chemotherapy regimens was similar in the two groups, and 65.5 and 69.5% of the patients, respectively, completed the planned 6 cycles.

**Non-hematological toxicity.** Fatigue was the most frequently recorded non-hematological side-effect associated with the one-week regimen and was significantly more frequent than with the three-week regimen (ANOVA; p<0.0001). This difference was noted for every individual cycle of the weekly schedule and the time-effect was also present with increasing fatigue during the treatment period (Table IV).

The second most common adverse event was watery eyes and tearing (epiphora), affecting 55 patients (50.9%) in the one-week group but only one patient (1.7%) in the three-week group. Thus, this side-effect was very specific for the weekly regimen and the frequency increased for every consecutive treatment cycle (Fig. 3).

### Statistical analysis

According to the inclusion and exclusion criteria, 108 patients were included in the one-week group and 59 in the three-week group. Originally the patients were recruited into two separate phase II studies during the same period of time. T-test, Pearson's Chi-square test and Fisher's exact test were used to compare continuous and non-continuous data. ANOVA (repeated measurements) was used to compare symptom scores during the whole period of treatment (cycles 1-6). A P-value <0.05 was considered to indicate a statistically significant result. STATISTICA software (StatSoft, Inc., Tulsa, OK, USA) version 10.0 was used for all statistical analyses in this study.

## Results

### Response and survival rates.

In the weekly schedule, 38 patients demonstrated a clinical complete response (44.7%), and 29 patients exhibited a partial response (34.1%), resulting in a total clinical response rate of 78.8% (95% CI, 70.1-87.5%). Data from the three-week schedule showed a clinical response rate of 88.7% (95% CI, 80.2-97.2%).

In the weekly schedule the median overall survival time was 35.3 months and the progression-free survival time was 12.0 months. The corresponding figures in the three-week schedule were 54.1 and 20.0 months, respectively.

Since this was not a randomized study, response and survival data could not be compared between the weekly and the three-week schedule due to differences in the study populations; this was not the purpose of the study.
Nail changes were relatively common with the weekly schedule and were reported in 30 cases (27.8%) compared with 9 cases (15.3%) with the three-week schedule (Fisher's exact test; p=0.049). Analyzed with ANOVA repeated test, significant differences (p<0.005) were shown after 3 courses of chemotherapy and until 6 completed courses as well as for the complete treatment (course 1-6). A significant time-dependent effect was noted after 3 cycles in the one-week group and after 5 cycles in the three-week group (p<0.0001).

With regard to peripheral neurotoxicity, no significant differences (ANOVA; p=0.125) were reported between the two treatment schedules, but a very pronounced time-effect was observed in both groups (ANOVA; p<0.0001; Table IV). After 6 completed courses of chemotherapy, 28 patients (39.4%) had grade 1-2 neurotoxicity in the weekly group and 13 patients (24.5%) in the three-week group. No patients exhibited grade 3 or higher sensory neuropathy (Table III).

Oral mucositis was significantly more common with the three-week schedule (ANOVA; p<0.0001) and increased in frequency from cycle 1 to cycle 3 and then reached a plateau and slightly decreased up to cycle 6. In the one-week group this was a less common problem but showed a slight increase with every consecutive cycle of treatment.

Taste disturbances were significantly more common after weekly treatment (ANOVA; p<0.0001) and showed a clear cut increase in frequency from the first to the fourth docetaxel cycle and then reached a plateau. In the three-week group this was a minor problem with a different time pattern (Table IV).

Myalgia following treatment was more pronounced with the three-week schedule than with weekly administration of docetaxel. The difference was highly significant (ANOVA; p<0.0001) during the complete period of treatment. There was no significant change in myalgia with time and this was true for both treatment groups (ANOVA; p=0.626).

Cardiac toxicity was extremely rare in the two groups. No significant differences were noted during the treatment period of six administered cycles of docetaxel-carboplatin (ANOVA; p=0.809). No significant time-dependent effect was noted in either group (ANOVA; p=0.210).

The mean score of nausea and vomiting was 14-15 on the scale of 1-100 in both groups after the first course of chemotherapy and then significantly decreased to ~6 after five courses of therapy (ANOVA; p<0.0001). There were no significant differences between the two chemotherapy regimens (ANOVA; p=0.277). Dyspnea and diarrhea were slightly more common after weekly administration of docetaxel but of limited clinical significance.

Fever and clinical infections were significantly more frequent after three-week administration of docetaxel than after weekly administration (ANOVA; p<0.0001; Fig. 2). This was possibly associated with neutropenia for the three-week schedule.
Table III. Non-hematological toxicity in the one-week and three-week groups.

| Type of toxicity | Grade 1 | Grade 2 | Grade 3 | Grade 4 | P-value $^b$ |
|------------------|---------|---------|---------|---------|-------------|
| Sensory neuropathy | 25 (35.2) | 3 (4.2) | 0 | 0 | 0.237 |
| One-week group | 25 (35.2) | 3 (4.2) | 0 | 0 | 0.237 |
| Three-week group | 12 (22.6) | 1 (1.9) | 0 | 1 (1.9) | 0.626 |
| Nausea | 11 (15.5) | 2 (2.8) | 1 (1.4) | 0 | 0.403 |
| One-week group | 10 (14.1) | 1 (1.4) | 0 | 0 | 0.125 |
| Three-week group | 4 (7.8) | 2 (3.9) | 0 | 0 | 0.125 |
| Mucositis | 6 (11.8) | 3 (5.9) | 2 (3.9) | 0 | 0.033 |
| One-week group | 10 (14.1) | 1 (1.4) | 0 | 0 | 0.033 |
| Three-week group | 4 (7.8) | 2 (3.9) | 0 | 0 | 0.033 |
| Nail changes | 1 (2.0) | 0 | 0 | 0 | 0.163 |
| Diarrhea | 9 (12.7) | 0 | 0 | 0 | 0.163 |
| One-week group | 9 (12.7) | 0 | 0 | 0 | 0.163 |
| Three-week group | 1 (2.0) | 0 | 0 | 0 | 0.163 |
| Myalgia | 3 (4.2) | 0 | 1 (1.4) | 0 | 0.042 |
| One-week group | 3 (4.2) | 0 | 1 (1.4) | 0 | 0.042 |
| Three-week group | 5 (9.8) | 2 (3.9) | 0 | 0 | 0.042 |
| Dyspnea | 9 (12.7) | 4 (5.6) | 1 (1.4) | 0 | 0.576 |
| One-week group | 9 (12.7) | 4 (5.6) | 1 (1.4) | 0 | 0.576 |
| Three-week group | 0 | 2 (3.9) | 0 | 0 | 0.576 |
| Cardiac | 2 (2.8) | 1 (1.4) | 1 (1.4) | 2 (2.8) | 0.576 |
| One-week group | 2 (2.8) | 1 (1.4) | 1 (1.4) | 2 (2.8) | 0.576 |
| Three-week group | 3 (5.9) | 1 (2.0) | 0 | 0 | 0.576 |
| Fever | 1 (1.4) | 3 (4.2) | 2 (2.8) | 0 | 0.824 |
| One-week group | 1 (1.4) | 3 (4.2) | 2 (2.8) | 0 | 0.824 |
| Three-week group | 1 (2.0) | 4 (8.0) | 1 (2.0) | 0 | 0.824 |
| Infection | 26 (36.1) | 7 (9.7) | 1 (1.4) | 0 | 0.496 |
| One-week group | 26 (36.1) | 7 (9.7) | 1 (1.4) | 0 | 0.496 |
| Three-week group | 15 (29.4) | 3 (5.9) | 0 | 0 | 0.496 |
| Fatigue | 1 (2.0) | 0 | 0 | 0 | 0.000 |
| One-week group | 1 (2.0) | 0 | 0 | 0 | 0.000 |
| Three-week group | 37 (52.1) | 7 (9.9) | 0 | 0 | 0.000 |
| Tearing eyes | 14 (27.5) | 3 (5.9) | 0 | 0 | 0.425 |
| Taste disturbances | 26 (36.3) | 6 (8.5) | 0 | 0 | 0.425 |

$^a$Toxicity grading after 6 completed courses of chemotherapy; $^b$Pearson Chi-square test.

**Discussion**

In order to improve the efficacy and tolerability of standard 3-week regimens of the combination of carboplatin and a taxane, the activity of weekly administration of docetaxel and 3-weekly carboplatin has been studied (17). This has not been performed previously in a first-line setting in primary advanced ovarian cancer. Katsumata et al (6) have investigated the efficacy of the combination of weekly dose-dense paclitaxel (80 mg/m$^2$) and carboplatin (AUC=6) compared
Table IV. Non-hematological toxicity in the one-week group and the three-week group during treatment (cycle 1-6). The toxicity grading is converted to a 0-100 linear scale according to the technique used for quality-of-life analysis (EORTC QLQ-C30 symptom scores).

| Toxicity                  | Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | Time | Group | TxG |
|---------------------------|---------|---------|---------|---------|---------|---------|------|-------|-----|
| Neutropathy sensory       |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 2.2     | 3.2     | 4.5     | 7.3     | 9.0     | 10.9    |      |       |     |
| Three-week group (B)      | 0.0     | 1.9     | 2.8     | 3.8     | 6.1     | 8.5     |      |       |     |
| P-value A vs. B           | 0.023   | 0.311   | 0.274   | 0.102   | 0.227   | 0.402   | 0.000 | 0.125 | 0.971 |
| Fatigue                   |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 8.1     | 11.5    | 13.7    | 14.0    | 15.1    | 14.9    |      |       |     |
| Three-week group (B)      | 0.0     | 1.4     | 1.9     | 1.0     | 1.9     | 10.3    |      |       |     |
| P-value A vs. B           | 0.000   | 0.000   | 0.000   | 0.000   | 0.000   | 0.000   | 0.000 | 0.000 | 0.004 |
| Nausea and vomiting       |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 14.0    | 12.3    | 8.6     | 7.9     | 9.0     | 6.3     |      |       |     |
| Three-week group (B)      | 15.0    | 15.6    | 12.0    | 9.9     | 5.3     | 8.8     |      |       |     |
| P-value A vs. B           | 0.750   | 0.293   | 0.238   | 0.428   | 0.226   | 0.417   | 0.000 | 0.277 | 0.610 |
| Myalgia                   |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 0.7     | 1.2     | 1.3     | 1.5     | 1.9     | 2.5     |      |       |     |
| Three-week group (B)      | 5.9     | 6.9     | 7.4     | 7.1     | 7.7     | 7.4     |      |       |     |
| P-value A vs. B           | 0.000   | 0.000   | 0.000   | 0.006   | 0.014   | 0.032   | 0.626 | 0.000 | 0.995 |
| Mucositis                 |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 2.5     | 5.4     | 5.2     | 4.3     | 4.2     | 4.2     |      |       |     |
| Three-week group (B)      | 6.5     | 8.8     | 13.4    | 12.7    | 12.5    | 9.8     |      |       |     |
| P-value A vs. B           | 0.025   | 0.180   | 0.001   | 0.000   | 0.002   | 0.013   | 0.001 | 0.000 | 0.106 |
| Taste disturbances        |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 5.6     | 10.3    | 13.0    | 13.4    | 12.8    | 13.4    |      |       | 5.9  |
| Three-week group (B)      | 0.0     | 1.9     | 0.9     | 1.9     | 1.4     | 1.4     |      |       |     |
| P-value A vs. B           | 0.000   | 0.000   | 0.000   | 0.000   | 0.006   | 0.001   | 0.000 | 0.003 | 0.012 |
| Nail changes              |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 0.7     | 1.7     | 4.2     | 4.6     | 9.6     | 10.2    |      |       |     |
| Three-week group (B)      | 0.0     | 0.0     | 0.0     | 0.0     | 1.4     | 4.9     |      |       |     |
| P-value A vs. B           | 0.201   | 0.085   | 0.005   | 0.006   | 0.000   | 0.001   | 0.000 | 0.003 | 0.012 |
| Dyspnea                   |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 1.5     | 1.5     | 2.1     | 3.4     | 3.6     | 7.0     |      |       |     |
| Three-week group (B)      | 0.0     | 0.0     | 0.0     | 3.3     | 0.5     | 2.0     |      |       |     |
| P-value A vs. B           | 0.115   | 0.169   | 0.079   | 0.981   | 0.058   | 0.046   | 0.002 | 0.010 | 0.113 |
| Cardiac toxicity          |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 0.2     | 1.5     | 3.6     | 3.0     | 2.6     | 5.3     |      |       |     |
| Three-week group (B)      | 0.5     | 1.9     | 2.3     | 4.7     | 1.4     | 2.5     |      |       |     |
| P-value A vs. B           | 0.658   | 0.808   | 0.577   | 0.533   | 0.547   | 0.342   | 0.210 | 0.809 | 0.399 |
| Epiphora                  |         |         |         |         |         |         |      |       |     |
| P-value A vs. B           | 0.201   | 0.013   | 0.000   | 0.000   | 0.000   | 0.000   | 0.000 | 0.000 | 0.000 |
| One-week group (A)        | 0.7     | 3.7     | 7.6     | 12.8    | 15.1    | 18.0    |      |       |     |
| Three-week group (B)      | 0.0     | 0.0     | 0.0     | 0.0     | 0.0     | 0.5     |      |       |     |
| P-value A vs. B           | 0.016   | 0.142   | 0.729   | 0.334   | 0.176   | 0.033   | 0.023 | 0.018 | 0.690 |
| Diarrhea                  |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 6.1     | 7.1     | 3.4     | 2.7     | 3.5     | 3.2     |      |       |     |
| Three-week group (B)      | 1.4     | 3.8     | 2.8     | 1.4     | 1.5     | 0.5     |      |       |     |
| P-value A vs. B           | 0.016   | 0.142   | 0.729   | 0.334   | 0.176   | 0.033   | 0.023 | 0.018 | 0.690 |
| Fever                     |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 0.7     | 0.2     | 1.3     | 0.6     | 1.9     | 0.7     |      |       |     |
| Three-week group (B)      | 0.0     | 6.5     | 7.9     | 3.3     | 4.8     | 7.8     |      |       |     |
| P-value A vs. B           | 0.465   | 0.003   | 0.005   | 0.014   | 0.119   | 0.010   | 0.059 | 0.000 | 0.024 |
| Infection                 |         |         |         |         |         |         |      |       |     |
| One-week group (A)        | 2.5     | 1.7     | 3.9     | 1.8     | 1.9     | 4.6     |      |       |     |
| Three-week group (B)      | 0.0     | 7.4     | 7.9     | 4.7     | 6.3     | 6.0     |      |       |     |
| P-value A vs. B           | 0.117   | 0.016   | 0.190   | 0.208   | 0.091   | 0.641   | 0.058 | 0.009 | 0.143 |
with paclitaxel (180 mg/m²) and carboplatin (AUC=6) every 3 weeks in patients with previously untreated ovarian cancer. The two regimens had relatively similar toxicity, but progression-free survival was significantly improved in the patients who received the dose-dense regimen (median 28 versus 17 months; p=0.0014). Weekly chemotherapy data have been reported in a number of previous studies (4,5). In our prior study (17) we encountered an overall response rate of 79%, which is superior to the 56% reported by Katsumata et al (8). Our data and results are in line with those of Micha et al (25) and Penson et al (26) who reported response rates of 80 and 76%, respectively, when adding bevacizumab to paclitaxel and carboplatin in the treatment of advanced-stage ovarian cancer.

The present study focuses on hematological and non-hematological toxicity when docetaxel is administered weekly compared with the standard 3-week schedule in combination with carboplatin given every three weeks. The dose-intensity of docetaxel was higher in the weekly schedule with 29.8 mg/m²/week compared to 25.1 mg/m²/week in the three-week schedule (t-test; p<0.001). The dose intensity of carboplatin was similar in the two regimens (t-test; p=0.211) with 105.7 and 109.4 mg/m²/week, respectively. Thus, differences in toxicity should be associated with the docetaxel treatment schedule. This was not a randomized study, but two separate first-line phase II studies of docetaxel in combination with carboplatin in the primary treatment of advanced ovarian cancer. The two study cohorts were similar with regard to the patients' characteristics, but with regard to the tumors there were slightly more endometrioid and more stage IIIB tumors in the three-week group, and more papillary serous and stage IV tumors in the one-week group. Distribution of the tumor grade was similar in the two groups. Response rates and survival data for the weekly schedule have been presented in a previous study (17). No comparison was made between the two regimens with regard to response rate and survival in the current study.

In terms of hematological toxicity, grade 3-4 neutropenia was recorded in 11% of the patients after six courses and weekly administration and in 78% after the standard three-week schedule. This was a highly significant difference and it was true during the whole course of chemotherapy from cycle 1 to cycle 6. The higher frequency of fever and infections recorded in the three-week group was probably explained by this myelosuppression. This difference in neutropenia (ANC) was the most important and clinically relevant difference between the two regimens. In a study from Germany, Sehouli et al (5) reported that 28% of their patients with advanced ovarian cancer developed grade 3-4 neutropenia after weekly paclitaxel (100 mg/m²) and carboplatin (AUC 2). Thrombocytopenia was infrequent and grade 3-4 was recorded in only one patient in the weekly group. However, grade 1-2 thrombocytopenia was more frequent in the one-week group (51%) than in the three-week group (17%), but this difference in laboratory readings had no clinical implications in this series of patients. None of the patients experienced grade 3-4 anemia. Grade 1-2 anemia was recorded in 96% of the weekly group and in 73% of the three-week administration group. This difference was statistically significant (Pearson Chi-square; p<0.0001), but clinically of minor importance. Overall, the hematological toxicity was quite manageable in both groups, but was more so in the weekly schedule with regard to the risk of neutropenia, fever and infections. Hematological toxicity (neutropenia) is also a common reason for not completing all planned courses of a chemotherapy regimen. Colony-stimulating factors were normally not used in these two phase II studies.

In the present study, sensory neuropathy grades 1 and 2 developed in 39.4% of patients in the one-week group and in 24.5% of those in the three-week group after six completed cycles of chemotherapy. Neuropathy significantly increased with time in both groups, but there were no significant differences between the two treatment regimens. None of the patients exhibited severe neurotoxicity grade 3. These results are comparable to those of Micha et al (25) and Sehouli et al (5) who reported low rates of severe peripheral neuropathy (2.3% grade 3). One would suspect that lower, weekly doses of taxanes would mitigate toxicity (4). However, Seidman et al (27) reported that neurotoxicity was a dose-limiting factor after weekly paclitaxel (80 mg/m²) for the treatment of metastatic breast cancer. Thus, docetaxel appears to have a lower rate of disabling neurotoxicity than paclitaxel when administered on a weekly schedule. However, the weekly schedule of docetaxel did not appear to be superior to a 3-week schedule of the same drug.

Epiphora was a type of toxicity recorded in 51% of the patients treated with the weekly schedule, but only in 1.7% of the patients with the three-week schedule. This toxicity appears to be specifically associated with weekly administration of docetaxel. Esmaeli et al (28) from the MD Anderson Cancer Center reported on 148 patients with this type of side-effect. Thirty of 71 patients given weekly docetaxel needed surgery to correct epiphora. Of the patients who received docetaxel every 2 or 3 weeks, only 3 required a surgical intervention to correct epiphora. A schedule of docetaxel given every 2 weeks has shown a favorable outcome and toxicity profile, also with regard to epiphora, and should be further evaluated in larger series of advanced ovarian cancer patients (29).

Fatigue was the most frequently reported side-effect and was particularly associated with the weekly regimen. The short interval (one week) between the administrations of docetaxel may explain this difference and time for recovery is therefore limited. Nail changes were also a common side-effect of the weekly schedule and were twice as common as in the three-week schedule. This side-effect has also been reported for weekly treatment with paclitaxel and is sometimes quite serious (30).

Oral mucositis may be a problem when higher doses of docetaxel are administered every three weeks (31). This was also confirmed in this study with significantly more mucositis in the three-week group. The incidence of mucositis reached a maximum after the third chemotherapy cycle with docetaxel. On the other hand, taste disturbances were significantly more common after weekly administration than after three-week administration.

Diarrhea and dyspnea were more frequent with the weekly schedule, but these side-effects appeared to be of less clinical significance and few patients reported these symptoms. Cardiac toxicity was also very rare and no differences between the two groups were recorded.

Fever and infections were significantly more frequent in the three-week group and this was a clinically important difference...
between the two schedules, favoring the weekly schedule. The more pronounced neutropenia after the standard three-week schedule is the probable reason for this difference (32).

In the current study the technique from the quality-of-life analysis (EORTC QLQ-C30) was used to calculate a symptom score on a linear scale from 0 to 100 for each symptom item (33). These scores were also used in the repeated ANOVA analyses when the two treatment schedules were compared over time. In these analyses the differences may be compared between the groups, as well as differences and patterns over time, and the combined effect of group and time.

Quality-of-life measurements were not part of this study, but data from the weekly schedule have been presented previously (18). The results from the quality-of-life data showed similar levels as for the standard carboplatin-paclitaxel regimen administered every three weeks (34). Peripheral neuropathy was one of the most notable side-effects affecting quality of life (35). Peripheral neuropathy is a minor problem for docetaxel compared with paclitaxel regimens in the treatment of ovarian cancer. This is the principal advantage of this taxane. One-third of patients undergoing cisplatin and paclitaxel treatment experienced long-term toxicity (36).

The two docetaxel schedules studied showed different toxicity profiles favoring weekly administration with regard to neutropenia, fever and infections as well as problems with oral mucositis and myalgia. Fatigue, epiphora, taste disturbances and nail changes were more specific side-effects of the weekly schedule and in a number of cases a clinical problem. Peripheral sensory neuropathy is a more limited problem with docetaxel compared with paclitaxel but no significant differences were noted between the two regimens studied.

Docetaxel is an alternative to paclitaxel in first-line and second-line chemotherapy regimens for advanced ovarian cancer. Dose-dense schedules with weekly or twice-weekly administrations of the drug should be further explored to improve and optimize the efficacy and the toxicity profile of docetaxel chemotherapy combinations.

Acknowledgements

The authors thank Sanofi-Aventis AB, Bromma, Sweden, for the financial support by grants.

References

1. Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CaseBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1748-1756, 1996.
3. Copeland LJ, Bookman M and Trimble E: Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5 Gynecol Oncol 90: S1-S7, 2003.
4. Safra T, Menczer J, Bernstein RM, et al: Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Gynecol Oncol 114: 215-218, 2009.
5. Sehouli J, Stengel D, Mustea A, et al: Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemospheracol 61: 243-250, 2008.
6. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, nonrandomised controlled trial. Lancet 374: 1331-1338, 2009.
7. Kavanagh JJ: Docetaxel in the treatment of ovarian cancer: Oncology 16: 73-81, 2002.
8. Katsumata N: Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 89: S9-S15, 2003.
9. Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691, 2004.
10. Kushner DM, Connor JP, Sanchez F, et al: Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol 105: 358-364, 2007.
11. Tinker AV, Gbeksi V, Fitzharris B, et al: Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel - ANZGOG 02-01. Gynecol Oncol 104: 647-653, 2007.
12. Gupta D, Owers RL, Kim M, et al: A Phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol 113: 327-330, 2009.
13. Safra T, Bernstein Molho R, Menzcher J, et al: A feasibility study of weekly docetaxel with capcitabine in ovarian cancer: a promising combination of two active drugs with a potential for dose-dense therapy. Chemotherapy 55: 298-302, 2009.
14. Terauchi F, Hirano T, Taoka H, et al: Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. Int J Clin Oncol 8: 348-351, 2003.
15. Berkenblit A, Seiden MV, Matulonis UA, et al: A Phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 95: 624-631, 2004.
16. Komiyama S, Tsuji H, Asai S, et al: A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer. Eur J Gynaecol Oncol 6: 299-302, 2005.
17. Sorbe B, Graflund M, Horvath G, Swahn M, Boman K, Bangshoj R, Lood M and Malmström H: Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIIB to stage IV epithelial ovarian cancer. Int J Gynecol Cancer 22: 47-53, 2012.
18. Sorbe B, Graflund M, Horvath G, Swahn M, Boman K, Bangshoj R, Lood M and Malmstrom H: A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 40: 773-781, 2012.
19. Calvert AH, Newell DR, Gunbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
20. Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
21. Green S and Weiss GR: Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-253, 1992.
22. Rustin GJ, Marples M and Nelstrop AE: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10: 3919-3926, 2004.
23. National Institute of Health: Common Terminology Criteria for Adverse Events (Version 3.0). National Institute of Health, Washington, DC, 2003.
24. Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual (3rd edition). EORTC publications, Brussels, Belgium, 2001.
25. Micha JP, Goldstein BH, Retenmaier MA, et al: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17: 771-776, 2007.
26. Penson RT, Dizon DS, Cannistra SA, et al: Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mullerian tumors. J Clin Oncol 28: 154-159, 2010.
27. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for HER-2 overexpressers and random assignment to trastuzumab or not in HER-2 nonoverexpressers: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26: 1642-1649, 2008.
28. Esmaeli B, Hidaji L, Adinin RB, et al: Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 98: 504-507, 2003.

29. Oishi T, Kigawa J, Fujiwara K, et al: A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol 90: 421-424, 2003.

30. Paul LJ and Cohen PR: Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent and beneath the nail. J Drugs Dermatol 11: 262-268, 2012.

31. Bezjak A, Tu D, Bacon M, et al: Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in randomized study. J Clin Oncol 22: 4595-4603, 2004.

32. Souglakos J, Kotsakis A, Kouroussis C, et al: Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. Cancer 95: 1326-1333, 2002.

33. Greimel ER, Bjelic-Radisic V, Pfisterer J, et al: Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24: 579-586, 2006.

34. Schwarz R and Hinz A: Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37: 1345-1351, 2001.

35. Almadrones L, McGuire DB, Walczak JR, et al: Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncol Nurs Forum 31: 615-623, 2004.

36. Wenzel L, Huang HQ, Monk BJ, et al: Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 23: 5605-5612, 2005.